Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

被引:101
作者
Olivier, RI
van Beurden, M
Lubsen, MAC
Rookus, MA
Mooij, TM
van de Vijver, MJ
van't Veer, LJ
机构
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Gynaecol, NL-1066 CX Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gynaecol, NL-1105 AZ Amsterdam, Netherlands
[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Epidemiol, NL-1066 CX Amsterdam, Netherlands
[4] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[5] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Family Canc Clin, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1038/sj.bjc.6601692
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingo-oophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women, who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years). These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower than among BRCA1 carriers.
引用
收藏
页码:1492 / 1497
页数:6
相关论文
共 40 条
[1]   Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or-2 mutations - Implications for gross examination, cytology, and clinical follow-up [J].
Agoff, SN ;
Mendelin, JE ;
Grieco, VS ;
Garcia, RL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (02) :171-178
[2]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[3]  
CHEN KTK, 1985, OBSTET GYNECOL S, V66, P93
[4]   Occult carcinoma in prophylactic oophorectomy specimens - Prevalence and association with BRCA germline mutation status [J].
Colgan, TJ ;
Murphy, J ;
Cole, DEC ;
Narod, S ;
Rosen, B .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (10) :1283-1289
[5]   COMPLICATIONS OF ABDOMINAL AND VAGINAL HYSTERECTOMY AMONG WOMEN OF REPRODUCTIVE AGE IN THE UNITED-STATES [J].
DICKER, RC ;
GREENSPAN, JR ;
STRAUSS, LT ;
COWART, MR ;
SCALLY, MJ ;
PETERSON, HB ;
DESTEFANO, F ;
RUBIN, GL ;
ORY, HW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1982, 144 (07) :841-848
[6]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[7]   Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer [J].
Eisen, A ;
Rebbeck, TR ;
Wood, WC ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) :1980-1995
[8]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[9]   RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].
FORD, D ;
EASTON, DF ;
BISHOP, DT ;
NAROD, SA ;
GOLDGAR, DE ;
HAITES, N ;
MILNER, B ;
ALLAN, L ;
PONDER, BAJ ;
PETO, J ;
SMITH, S ;
STRATTON, M ;
LENOIR, GM ;
FEUNTEUN, J ;
LYNCH, H ;
ARASON, A ;
BARKARDOTTIR, R ;
EGILSSON, V ;
BLACK, DM ;
KELSELL, D ;
SPURR, N ;
DEVILEE, P ;
CORNELISSE, CJ ;
VARSEN, H ;
BIRCH, JM ;
SKOLNICK, M ;
SANTIBANEZKOREF, MS ;
TEARE, D ;
STEEL, M ;
PORTER, D ;
COHEN, BB ;
CAROTHERS, A ;
SMYTH, E ;
WEBER, B ;
NEWBOLD, B ;
BOEHNKE, M ;
COLLINS, FS ;
CANNONALBRIGHT, LA ;
GOLDGAR, D .
LANCET, 1994, 343 (8899) :692-695
[10]   Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study [J].
Foulkes, WD ;
Narod, SA ;
Swenerton, K ;
Panabaker, K ;
Gilbert, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (21) :1640-1640